Does escitalopram reduce neurotoxicity in major depression?

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Psychiatric Research

• Publication date

  2015-07-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.jpsychires.2015.04.026PMID 26009299
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis.

  2014cited by this paper
• No evidence for an anti-inflammatory effect of escitalopram intervention in healthy individuals with a family history of depression.

  2012cited by this paper
• Interleukin-1β: A New Regulator of the Kynurenine Pathway Affecting Human Hippocampal Neurogenesis

  2012cited by this paper
• New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio

  2012cited by this paper
• Effects of antidepressants and cyclooxygenase-2 inhibitor on cytokines and kynurenines in stimulated in vitro blood culture from depressed patients

  2012cited by this paper
• Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability

  2012cited by this paper
• Kynurenines: from the perspective of major psychiatric disorders

  2012cited by this paper
• Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression

  2011cited by this paper
• Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study

  2011cited by this paper
• The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis

  2011cited by this paper
• Efficacy of escitalopram compared to citalopram: a meta-analysis.

  2011cited by this paper
• A psychoneuroimmunological review on cytokines involved in antidepressant treatment response

  2010cited by this paper
• ResearchAttention-deficit hyperactivity disorder ( ADHD ) and glial integrity : S 100 B , cytokines and kynurenine metabolism-effects of medication

  2010cited by this paper
• Pro-inflammatory biomakers in depression: Treatment with venlafaxine

  2009cited by this paper
• Escitalopram in the treatment of major depressive disorder: A meta-analysis

  2009cited by this paper
• Escitalopram in the treatment of major depressive disorder: a meta-analysis.

  2009cited by this paper
• Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder.

  2008cited by this paper
• Kynurenine pathway in major depression: evidence of impaired neuroprotection.

  2007cited by this paper
• Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.

  2007cited by this paper
• Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost‐effectiveness vs. venlafaxine extended‐release formulation

  2007cited by this paper
• Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.

  2006cited by this paper
• Increase in interleukin-1 beta in late-life depression

  2005cited by this paper
• Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity.

  2005cited by this paper
• Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder

  2005cited by this paper
• Increase in interleukin-1beta in late-life depression.

  2005cited by this paper
• Th1, Th2, and Th3 cytokine alterations in major depression.

  2005cited by this paper
• Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression.

  2003cited by this paper
• Concurrent quantification of quinolinic, picolinic, and nicotinic acids using electron-capture negative-ion gas chromatography-mass spectrometry.

  2002cited by this paper
• The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs

  2002cited by this paper
• Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis.

  2001cited by this paper
• Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages.

  2001cited by this paper
• Cytokine Production and Treatment Response in Major Depressive Disorder

  2000cited by this paper
• Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features

  1999cited by this paper
• Depression, stress and immunological activation: the role of cytokines in depressive disorders.

  1998cited by this paper
• Interleukin-1 Enhances Indoleamine 2,3-Dioxygenase Activity by Increasing Specific mRNA Expression in Human Mononuclear Phagocytes

  1995cited by this paper
• Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human monocytes.

  1994cited by this paper
• Relationship between interferon‐γ, indoleamine 2,3‐dioxygenase, and tryptophan catabolism

  1991cited by this paper
• Interferon‐lnduced Indoleamine 2,3‐Dioxygenase Activity in Human Mononuclear Phagocytes

  1989cited by this paper
• Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures.

  1987cited by this paper
• Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients.

  1986cited by this paper
• Kynurenine hydroxylase: a potential rate-limiting enzyme in tryptophan metabolism.

  1985cited by this paper
• An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid.

  1982cited by this paper
• Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect.

  1969cited by this paper
• ORIGINAL ARTICLE Indian Journal of Psychiatry, 2004, 46(4)333-341 Escitalopram Versus Citalopram And Sertraline: A Double–Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression

  year unknowncited by this paper

• Kynurenine pathway dysregulation in major depressive disorder: the convergence of excitotoxicity, neuroinflammation, and oxidative stress.

  2026cites this paper
• Serotonin Signaling Pathway Modulation Affects Retinal Neuron Survival in Experimental Model of Retinal Ischemia

  2025cites this paper
• Immunomodulatory Potential of Escitalopram on C‐C Motif Chemokine Ligand 5 and Fibroblast Growth Factor 2 in Patients With Generalised Anxiety Disorder

  2025cites this paper
• Alterations in serum nudifloramide associated with response to diverse pharmacological treatments in major depressive disorder: a preliminary study

  2025cites this paper
• The adjunct role of pharmacotherapy in multimodal treatment of paediatric functional neurological disorder

  2025cites this paper
• Neurochemical Insights into the Role of Tryptophan Metabolites and Kynurenine Pathway in Insomnia and its Psychological and Neurological Comorbidities

  2025cites this paper
• Modern Concept of Depression Pathogenesis: The Contribution of I.P. Lapin’s Research Team

  2025cites this paper
• Galantamine as add-on therapy to escitalopram: enhancing antidepressant therapeutic potential via. Targeting α7nAChR/BDNF/KYN signalling

  2025cites this paper
• Changes in schizophrenia symptoms, tryptophan metabolism, neuroinflammation and the GABA-glutamate loop: A pilot study

  2025cites this paper
• Immune Dysregulation in Depression and Anxiety: A Review of the Immune Response in Disease and Treatment

  2025cites this paper
• Electroacupuncture versus Escitalopram for mild to moderate Post-Stroke Depression: A randomized non-inferiority trial

  2024cites this paper
• Interleukin-8 is a potential inflammation biomarker in major depressive disorder

  2024cites this paper
• Kynurenine pathway in type 2 diabetes: Role of metformin

  2024cites this paper
• Understanding the kynurenine pathway: A narrative review on its impact across chronic pain conditions

  2024cites this paper
• Changes in tryptophan breakdown associated with response to multimodal treatment in depression

  2024cites this paper
• Low-grade inflammation and serotonin 4 receptor binding in the healthy and the depressed brain

  2024cites this paper
• Sildenafil, alone and in combination with imipramine or escitalopram, display antidepressant-like effects in an adrenocorticotropic hormone-induced (ACTH) rodent model of treatment-resistant depression.

  2024cites this paper
• Dysfunction in endocannabinoids, palmitoylethanolamide, and degradation of tryptophan into kynurenine in individuals with depressive symptoms

  2024cites this paper
• Kynurenine pathway of tryptophan metabolism in pathophysiology and therapy of major depressive disorder

  2023cites this paper
• White matter integrity and pro-inflammatory cytokines as predictors of antidepressant response in MDD.

  2023cites this paper
• The kynurenine pathway in major depressive disorder under different disease states: A systematic review and meta-analysis.

  2023cites this paper
• Pro-inflammatory markers are associated with response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 report

  2023cites this paper
• Anti-inflammatory properties of commonly used psychiatric drugs

  2023cites this paper
• Autonomic Measures in Differentiating Depressive Disorders: A Potential AID

  2022cites this paper
• Changes in Tryptophan-Kynurenine Metabolism in Patients with Depression Undergoing ECT—A Systematic Review

  2022cites this paper
• KXS Balances the Tryptophan Metabolism in Mild to Moderate Depressed Patients and Chronic Restraint Stress Induced Depressive Rats

  2022cites this paper
• Cardiolipin Antibody: A Potential Biomarker for Depression

  2022cites this paper
• Acute administration of ibuprofen increases serum concentration of the neuroprotective kynurenine pathway metabolite, kynurenic acid: a pilot randomized, placebo-controlled, crossover study

  2022cites this paper
• C-Reactive Protein in Major Depressive Disorder: Promise and Challenge

  2022cites this paper
• Tryptophan Metabolism in Depression: A Narrative Review with a Focus on Serotonin and Kynurenine Pathways

  2022cites this paper
• IDO/kynurenine pathway in cancer: possible therapeutic approaches

  2022cites this paper
• The Footprint of Kynurenine Pathway in Cardiovascular Diseases

  2022cites this paper
• Imbalances in Kynurenines as Potential Biomarkers in the Diagnosis and Treatment of Psychiatric Disorders

  2022cites this paper
• Inflammation and serotonin deficiency in major depressive disorder: molecular docking of antidepressant and anti-inflammatory drugs to tryptophan and indoleamine 2,3-dioxygenases

  2022cites this paper
• Depression, Estrogens, and Neuroinflammation: A Preclinical Review of Ketamine Treatment for Mood Disorders in Women

  2022cites this paper
• Effects of Antidepressant Treatment on Peripheral Biomarkers in Patients with Major Depressive Disorder (MDD)

  2021influential citation
• The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment

  2021cites this paper
• The relationship between plasma cytokine levels and antidepressant response in patients with first-episode major depressive disorder.

  2021cites this paper
• Targeting the CCL2-CCR2 axis in depressive disorders

  2021cites this paper
• The kynurenine pathway in major depression: What we know and where to next.

  2021cites this paper
• The Kynurenine Pathway in Traumatic Brain Injury: Implications for Psychiatric Outcomes.

  2021cites this paper
• Neuroinflammation and the Kynurenine Pathway in CNS Disease: Molecular Mechanisms and Therapeutic Implications

  2021cites this paper
• Effects of antidepressant drug therapy with or without physical exercise on inflammatory biomarkers in major depressive disorder: a systematic review and meta-analysis of randomized controlled trials

  2021cites this paper
• Vascular endothelial growth factor in bipolar depression: A potential biomarker for diagnosis and treatment outcome prediction.

  2020cites this paper
• The Role of Exercise in Management of Mental Health Disorders: An Integrative Review.

  2020cites this paper
• Behavioral activation therapy for depression is associated with a reduction in the concentration of circulating quinolinic acid

  2020cites this paper
• The anti-inflammatory role of SSRI and SNRI in the treatment of depression: a review of human and rodent research studies

  2020cites this paper
• Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis

  2020cites this paper
• Neurobiology of Impulsivity and Aggression as Substrates of Suicidal Behavior: A Narrative Focus on the Involvement of Serum Lipids

  2020cites this paper
• Effects of Adjunctive Inflammatory Modulation on IL-1β in Treatment Resistant Bipolar Depression.

  2020cites this paper
• Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca

  2020cites this paper
• Plasma Neuronal and Glial Markers and Anterior Cingulate Metabolite Levels in Major Depressive Disorder: A Pilot Study

  2020cites this paper
• The Relationship between Plasma Serotonin and Kynurenine Pathway Metabolite Levels and the Treatment Response to Escitalopram and Desvenlafaxine.

  2020cites this paper
• Effects of inflammation modulation on tryptophan and kynurenine pathway regulation in treatment resistant bipolar depression

  2019cites this paper
• Apical Periodontitis Is Associated with Elevated Concentrations of Inflammatory Mediators in Peripheral Blood: A Systematic Review and Meta-analysis.

  2019cites this paper
• Immunology for palliative medicine specialists. The role of Toll-like receptors in inducing disease symptoms

  2019cites this paper
• Celecoxib augmentation of escitalopram in treatment-resistant bipolar depression and the effects on Quinolinic Acid

  2019cites this paper
• Unraveling the complex interplay of immunometabolic systems that contribute to the neuroprogression of psychiatric disorders

  2019cites this paper
• Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: A systematic review and meta-analysis.

  2019cites this paper
• Sex Specific Changes in Tryptophan Breakdown Over a 6 Week Treatment Period

  2019cites this paper
• Suicide and Microglia: Recent Findings and Future Perspectives Based on Human Studies

  2019cites this paper
• Longitudinal association of inflammation with depressive symptoms: A 7-year cross-lagged twin difference study.

  2019cites this paper
• A review on inflammatory cytokine-induced alterations of the brain as potential neural biomarkers in post-traumatic stress disorder.

  2019cites this paper
• Low cardiac vagal tone index by heart rate variability differentiates bipolar from major depression

  2019cites this paper
• Neuroinflammation and neurotoxicity contribute to neuroprogression in neurological and psychiatric disorders

  2018cites this paper
• Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models

  2018cites this paper
• Prolonged therapy with antidepressants increases hippocampal level of kynurenic acid and expression of Kat1 and Kat2 genes

  2018cites this paper
• Kynurenine pathway in depression: A systematic review and meta‐analysis

  2018cites this paper
• Effect of antidepressant treatment on peripheral inflammation markers - A meta-analysis.

  2018cites this paper
• The anti-inflammatory mechanism of antidepressants - SSRIs, SNRIs.

  2018cites this paper
• Changes in the tryptophan-kynurenine axis in association to therapeutic response in clinically depressed patients undergoing psychiatric rehabilitation.

  2018cites this paper
• Tryptophan-kynurenine and lipid related metabolites as blood biomarkers for first-episode drug-naïve patients with major depressive disorder: An exploratory pilot case-control study.

  2018cites this paper
• Plasma C-reactive protein levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment.

  2018cites this paper
• Pharmacological and Nonpharmacological Interventions to Arrest Neuroprogression in Psychiatric Disorders.

  2017cites this paper
• Heart Rate Variability Predicts Treatment Outcome in Major Depression

  2017cites this paper
• How to: Measuring blood cytokines in biological psychiatry using commercially available multiplex immunoassays.

  2017cites this paper
• Rescue of IL-1β-induced reduction of human neurogenesis by omega-3 fatty acids and antidepressants

  2017cites this paper
• Inflammation-Associated Co-morbidity Between Depression and Cardiovascular Disease.

  2017cites this paper
• Drugs with antidepressant properties affect tryptophan metabolites differently in rodent models with depression‐like behavior

  2017influential citation
• Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis

  2017cites this paper
• CAN INFECTION LEAD TO MENTAL ILLNESS?

  2016cites this paper
• Polyprenylated Tetraoxygenated Xanthones from the Roots of Hypericum monogynum and Their Neuroprotective Activities.

  2016cites this paper
• Panels of inflammation biomarkers, growth factors and kynurenine metabolites aid in stratification of depressed patients

  2016cites this paper
• THE PHARMACODYNAMICS OF MEDICATIONS USED IN PSYCHIATRIC DISORDERS

  2016cites this paper
• Cognition and Emotions in Recurrent Depressive Disorders - The Role of Inflammation and the Kynurenine Pathway.

  2016cites this paper